temozolomide has been researched along with losartan potassium in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Ehrenreich, H; Giese, A; Hasselblatt, M; Hassouna, I; Jelkmann, W; Kim, E; Rave-Fränk, M; Schulz-Schaeffer, W; Sperling, S | 1 |
2 other study(ies) available for temozolomide and losartan potassium
| Article | Year |
|---|---|
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Erythropoietin augments survival of glioma cells after radiation and temozolomide.
Topics: Animals; Antineoplastic Agents, Alkylating; Brain Neoplasms; Cell Division; Cell Line, Tumor; Cell Movement; Cell Survival; Combined Modality Therapy; Dacarbazine; Erythropoietin; Glioma; Gliosarcoma; Humans; Mice; Mice, Nude; Neoplasm Transplantation; Temozolomide; Transplantation, Heterologous | 2008 |